Michael A. Metzger

President, Chief Operating Officer & Director at Syndax Pharmaceuticals, Inc.

Michael A. Metzger

Michael A. Metzger

President, Chief Operating Officer & Director at Syndax Pharmaceuticals, Inc.

Overview
Career Highlights

Syndax Pharmaceuticals, Inc.
Mersana Therapeutics, Inc.
Tobira Therapeutics, Inc.

RelSci Relationships

562

Number of Boards

7

Birthday

1971

Age

48

Relationships
RelSci Relationships are individuals Michael A. Metzger likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Tarveda Therapeutics, Inc.

Relationship likelihood: Strong

Senior Advisor, Life Sciences Team at Frazier Healthcare Partners

Relationship likelihood: Strong

Executive Partner at Mpm Capital LLC

Relationship likelihood: Strong

Partner at Domain Associates LLC

Relationship likelihood: Strong

Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at CTI BioPharma Corp.

Relationship likelihood: Strong

Executive Vice President & Chief Financial Officer at CTI BioPharma Corp.

Relationship likelihood: Strong

Chief Financial Officer, Treasurer & Principal Accounting Officer at Syndax Pharmaceuticals, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Tobira Therapeutics, Inc.

Relationship likelihood: Strong

Partner at Domain Associates LLC

Relationship likelihood: Strong

Paths to Michael A. Metzger
Potential Connections via
Relationship Science
You
Michael A. Metzger
President, Chief Operating Officer & Director at Syndax Pharmaceuticals, Inc.
Education
BA

The George Washington University actively engages Washington, D.C., and the world. Their location in the heart of Washington places them at the core of U.S. government, policy and law. They sit where the worlds of science, technology, media and the arts converge. Their students and faculty have the unparalleled opportunity to study and work alongside leaders and practitioners in every discipline, to take part in the interchanges that shape our community and the world. The George Washington University was created in 1821 through an Act of Congress, fulfilling George Washington’s vision of an institution in the nation’s capital dedicated to educating and preparing future leaders. Today, GW is the largest institution of higher education in the District of Columbia. They have more than 20,000 students—from all 50 states, the District and more than 130 countries—studying a rich range of disciplines: from forensic science and creative writing to international affairs and computer engineering, as well as medicine, public health, the law and public policy. GW comprises three campuses—Foggy Bottom and Mount Vernon in Washington, D.C., and the GW Virginia Science and Technology Campus in Ashburn, Va.—as well as several graduate education centers in the metropolitan area and Hampton Roads, Va.

MBA in Finance

Since its inception in 1900, New York University Stern School of Business has been in and of New York City. Founded as the School of Commerce, Finance, and Accounting, the School initially offered training to students for careers in commerce in the burgeoning financial markets of New York City. Today, located in the heart of Greenwich Village with a campus in Westchester, Stern is one of the nation’s premier management education schools and research centers with a broad portfolio of academic programs at the graduate and undergraduate levels. With its global partnerships and engagement in NYU’s global network university, today NYU Stern is not only in and of the city, but also in and of the world.

Career History
President, Chief Operating Officer & Director
2015 - Current

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

President, Chief Executive & Operating Officer
Prior - 2015

Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on May 4, 2015 and is headquartered in South San Francisco, CA.

Chief Executive Officer, President & Chief Operating Officer
2013 - 2015

Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a \"per patient, per setting\" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ.

Boards & Committees
Independent Director
2010 - 2013

Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer. Its platforms include analysis of single biomarkers using the polymerase chain reaction method as well as global gene interrogation using microarray methods from paraffin or frozen tissue specimens. It also provides pharmacogenomic testing services of clinical trial specimens to pharmaceutical companies. The company was founded by David A. Smith and Kathleen Danenberg on September 23, 1999 and is headquartered in Los Angeles, CA.

Transactions
Details Hidden

Syndax Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Syndax Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Regado Biosciences, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michael A. Metzger. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michael A. Metzger's profile does not indicate a business or promotional relationship of any kind between RelSci and Michael A. Metzger.